secwatch.observer — SEC 8-K summary
======================================

Issuer:     Transcode Therapeutics, Inc. (RNAZ)
CIK:        0001829635
Form:       8-K
Filed at:   2023-08-04T23:59:59+00:00
Accession:  0001104659-23-087574
Event type: regulatory
Sentiment:  negative
Materiality: 0.90
Item codes: 3.01
LLM model:  deepseek-v4-flash:cloud@v2

TransCode Therapeutics faces Nasdaq delisting after compliance plan rejected; hearing set for Oct 2023
--------------------------------------------------------------------------------

- Nasdaq rejected compliance plan on July 26, 2023, for failing to meet $2.5M stockholders' equity requirement.
- Company appealed; oral hearing before Nasdaq Hearings Panel scheduled for October 2023.
- Delisting action stayed until hearing held and final written decision issued.
- No assurance that plan will be accepted or that compliance can be regained.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1829635/000110465923087574/0001104659-23-087574-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1829635/000110465923087574/tm2322857d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-23-087574

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer